

WEGOVY SEMAGLUTIDE & BUY ALERT

NOVO NORDISK A/S (NVO)

01/04/2023

Wegovy

the new weight loss
medication



INTRODUCTION - What is Wegovy?

Wegovy (semaglutide) developed and manufactured by Novo Nordisk A/S is a prescription medication used for chronic weight management in adults with obesity or overweight and at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by increasing feelings of fullness and reducing hunger, leading to a reduction in calorie intake and weight loss.

Wegovy is administered as a once-weekly injection under the skin and is typically used in combination with a reduced-calorie diet and increased physical activity. It is **approved by the U.S. Food and Drug Administration (FDA)** for use in adults with a body mass index (BMI) of 27 or greater who have at least one weight-related condition, or in adults with a BMI of 30 or greater.

Clinical studies have shown that Wegovy can lead to significant weight loss when used as directed, with some patients losing up to 15% of their initial body weight. However, it may not be appropriate for everyone and should only be used under the guidance of a healthcare provider. It is important to note that Wegovy is not a "magic pill" and weight loss results will vary depending on individual factors such as diet, exercise, and overall health.


Novo Nordisk is a global healthcare company based in Denmark that specializes in diabetes care and other chronic conditions such as obesity, hemophilia, and growth disorders.




Important Facts About Novo Nordisk (NVO)

1. **Founded in 1923:** Novo Nordisk was founded in Denmark in 1923 by August Krogh and Marie Krogh as Nordisk Insulinlaboratorium. The company merged with another Danish insulin producer, Novo Terapeutisk Laboratorium, in 1989 to form Novo Nordisk.
2. **Focus on diabetes care:** Novo Nordisk is the world's largest producer of insulin and has a strong focus on diabetes care. The company offers a range of insulin products, as well as other medications, devices, and digital solutions for diabetes management.
3. **Global presence:** Novo Nordisk operates in more than 80 countries worldwide and employs over 45,000 people. The company has production facilities in several countries, including Denmark, the United States, Brazil, and China.
4. **Commitment to sustainability:** Novo Nordisk has a strong commitment to sustainability and has set ambitious goals for reducing its environmental impact and improving access to healthcare. The company aims to be climate-neutral by 2030 and has set a goal to provide access to diabetes care to 100 million people by 2030.
5. **Ongoing research and development:** Novo Nordisk invests heavily in research and development to develop new treatments for chronic conditions. The company has several pipeline products in development, including medications for obesity, diabetes, and other conditions.

[Click to watch: Does Wegovy help to lose weight? - Good Morning America](#)



Wegovy STEP 1 Clinical Trial Results



Approved by the FDA and recognised by the WHO

Wegovy (semaglutide) has been approved by both the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) for the treatment of obesity.

The WHO has included semaglutide in its Model List of Essential Medicines, which is a list of the most effective and safe medicines needed in a health system. The inclusion of semaglutide in this list indicates its importance in treating obesity and underscores its potential to improve global public health.

In the United States, Wegovy was approved by the FDA in June 2021 as a once-weekly injection for chronic weight management in adults with obesity or overweight and at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. The approval was based on the results of clinical trials demonstrating significant weight loss with semaglutide treatment compared to placebo.

The FDA approval of Wegovy was seen as a significant milestone in the treatment of obesity, as there are currently limited options for medical treatment of this condition. Semaglutide's approval as a weight loss medication is expected to provide an important new tool for healthcare providers to help their patients achieve and maintain a healthy weight.

RENEW
VITALITY

How the new weight-loss shot works

1



Injection **once** a week

Depending on the body's response to treatment. Physicians may increase the dosage weekly based on patients feedback.

2



Suppresses hunger by mimicking hormone that **tells brain it's full**

3



Causes food to clear from stomach **more slowly**

Feel full even after eating small portions, helping them to lose weight in the process.

4



Obese people lost a fifth of their body weight in **72 weeks** in study

Key Partners of Novo Nordisk A/S

Novo Nordisk collaborates with various partners in academia, healthcare, and industry to advance research and innovation in healthcare. Some of the company's key partners include:

1. **Healthcare providers:** Novo Nordisk works closely with healthcare providers, including doctors, nurses, and diabetes educators, to improve patient care and promote education on diabetes management.
2. **Patient organizations:** The company partners with patient organizations to raise awareness of diabetes and other chronic conditions and provide support to patients and their families.
3. **Universities and research institutions:** Novo Nordisk collaborates with leading universities and research institutions around the world to advance scientific research and development of new treatments for diabetes and other chronic conditions.
4. **Technology companies:** The company partners with technology companies to develop and implement digital solutions for diabetes management and patient support.
5. **Government agencies:** Novo Nordisk works with government agencies and regulators to ensure compliance with regulations and promote access to healthcare for patients.
6. **Other industry partners:** Novo Nordisk partners with other companies in the healthcare industry to develop new treatments, improve patient care, and advance innovation.

Novo Nordisk and UNICEF in new partnership to prevent childhood overweight and obesity. Their strategy aims to reduce global obesity by 25% by 2045, reaching more than half a million children in Latin America by 2023.

Overall, Novo Nordisk values collaboration and works with a diverse range of partners to achieve its mission of improving healthcare and helping patients with chronic conditions live healthy, fulfilling lives.

Global Obesity and Diabetes Rates

1. Obesity is a growing epidemic: According to the World Health Organization (WHO), worldwide obesity has nearly tripled since 1975, and in 2016, more than 1.9 billion adults were overweight, with over 650 million of those being obese.
2. Obesity and diabetes are closely linked: Obesity is a major risk factor for type 2 diabetes, as excess body fat can make it difficult for the body to use insulin effectively. According to the International Diabetes Federation (IDF), in 2019, there were 463 million adults worldwide living with diabetes, and this number is expected to increase to 700 million by 2045.
3. The economic impact of obesity and diabetes is significant: The cost of obesity and diabetes to healthcare systems and economies is substantial. The IDF estimates that in 2019, the global healthcare expenditure on diabetes was \$760 billion, and the total economic cost of diabetes was \$1.3 trillion. The economic impact of obesity is also significant, with estimates suggesting that it costs the world economy \$2 trillion annually.
4. Rates of obesity and diabetes vary by region: Rates of obesity and diabetes vary widely by region and country. According to the WHO, the prevalence of obesity in adults in 2016 was highest in the Americas (over 62% in some countries) and lowest in South-East Asia (less than 4% in some countries). The IDF reports that the highest prevalence of diabetes in adults in 2019 was in the Western Pacific region, followed by the Middle East and North Africa.
5. Prevention and management are key: Effective prevention and management of obesity and diabetes are essential to reducing the burden of these conditions on individuals and societies. Lifestyle interventions, including diet and exercise, are important in preventing and managing obesity and diabetes, and medications like semaglutide (Wegovy) can also be effective in some cases. Access to healthcare and education is crucial to improving prevention and management efforts globally.

Why is the partnership needed?

From 2000 to 2016, the proportion of overweight children between 5 and 19 years of age nearly doubled from **1 in 10** to almost **1 in 5**¹



Childhood obesity has varied and complex causes, and is increasing at an alarming rate³



Children who have overweight are at a higher risk of developing chronic non-communicable diseases (NCDs), like heart disease and type 2 diabetes⁴




Effective prevention of childhood overweight and obesity will require collaboration across multiple groups and industries⁴

40
MILLION


children under the age of 5 are living with overweight or obesity²

Analysts ratings on NVO as of 1st April 2023

Analyst Rating Consensus



LLY Stock Price Prediction



Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years.

Novo Nordisk is bolstering its market dominance in diabetes, a disease that affects some 415 million people worldwide, with numbers growing all the time. By 2040, there will be more than half a billion patients, according to the Centers for Disease Control and Prevention.

So it comes as little surprise that in 2022, Novo Nordisk made 177 billion Danish kroner in sales (US \$25.8 billion), a 26% increase in its native currency, and a 16% increase at constant exchange rates (CER). Net profit was 55.5 billion kroner (US \$8.1 billion), up 16% in that currency.

How do I trade/buy Novo Nordisk?

You will be able to trade NVO using our instruments at Foresight Alternatives Limited. Contact our advisors for further details of our institutional pricing and stay ahead of the curve.

Although the material contained in this report was prepared based on information from public and private sources that Foresight Alternatives Limited believes to be reliable, no representation, warranty or undertaking, stated or implied, is given as to the accuracy of the information contained herein, and Foresight Alternatives Limited expressly disclaims any liability for the accuracy and completeness of information contained in this report.

This report is distributed for general informational and educational purposes only and is not intended to constitute legal, tax, accounting or investment advice. The information, opinions and views contained herein have not been tailored to the investment objectives of any one individual, are current only as of the date hereof and may be subject to change at any time without prior notice. Foresight Alternatives Limited does not have any obligation to provide revised opinions in the event of changed circumstances. All investment strategies and investments involve risk of loss. Nothing contained in this report should be construed as investment advice. Any reference to an investment's past or potential performance is not, and should not be construed as, a recommendation or as a guarantee of any specific outcome or profit.

Any ideas or strategies discussed herein should not be undertaken by any individual without prior consultation with a financial professional for the purpose of assessing whether the ideas or strategies that are discussed are suitable to you based on your own personal financial objectives, needs and risk tolerance. Foresight Alternatives Limited expressly disclaims any liability or loss incurred by any person who acts on the information, ideas or strategies discussed herein.